Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan
March 12, 2024
- Xolair SC Pen Versions Approved in Japan: Novartis
March 11, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- Japan Ethical Drug Sales Rise 5.6% in January: Crecon
March 8, 2024
- Keytruda Top-Seller Drug for 5th Straight Month in February: Encise
March 8, 2024
- Japan Generic Makers See Smaller Price Cuts in FY2024: Jiho Survey
March 7, 2024
- Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
- Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
March 7, 2024
- Eisai Pledges Up to US$15 Million for Alzheimer’s Blood Test Player
March 7, 2024
- Takeda Triples Entyvio Production Capacity at Japan Site
March 7, 2024
- Sumitomo Pharma to Ax 400 US Jobs as it Rejigs North American Biz
March 7, 2024
- Ono Bags Cancer Drug License from South Korea’s NEX-I
March 7, 2024
- Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
- Shionogi/Nagasaki University Enter New Phase of Malaria Collab, Aim for Clinical Trials
March 6, 2024
- Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
- Mitsubishi, Daiichi Sankyo to Wind Up Diabetes Collab
March 6, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Shionogi, FunPep Enter Option Deal for Pollen Allergy Vaccine
March 6, 2024
- Astellas Kicks Off Japan PIII Studies for Hot Flash Med
March 5, 2024
- EU Regulators Accept Daiichi Sankyo’s TROP2 ADC for Review in Lung, Breast Cancers
March 5, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…